NCT00561197终止1 期
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Ascenta Therapeutics1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2007年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Phase 1: Safety and tolerability of AT-101 in combination with chemoradiotherapy, and determine a dose for Phase 2. Phase 2: Determine the pathologic complete response (pathCR) rate and to correlate tumor biomarker expression with clinical response.
研究概览
简要总结
This is a Phase 1/ 2, open-label, single-center study of preoperative chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients age ≥18 years
- •Histologically confirmed primary (non-recurrent) adenocarcinoma (AC) or squamous cell carcinoma of the esophagus or AC of the gastroesophageal (GE) junction.
- •For Phase 1: Phase 1 patients must have unresectable disease (Stage II to IVa). A patient can be unresectable for medical reasons or technical reasons but eligible for chemoradiation.
- •For Phase 2: Phase 2 patients must have resectable cancer defined as: T2, T3, N0; OR T1-3, N+
- •Patients must have archived tumor tissue to correlate tumor biomarker expression with clinical response. Availability of tumor specimens in paraffin blocks or at least two unstained slides must be confirmed prior to study entry. Results will not be used to determine patient eligibility for the study.
- •ECOG performance status 0-1
- •Adequate hematologic function
- •Adequate liver and renal function
- •Ability to swallow and retain oral medication.
排除标准
- •Patients with distant metastasis, including M1b lymph node status. (M1b status allowed on Phase I only for patients appropriate for chemoradation). Lymph nodes suspicious of M1b status by diagnostic imaging must be verified by fine-needle aspiration cytology. (Phase 2 only)
- •For Phase 2: Patients with positive pleural, pericardial, or peritoneal cytology.
- •For Phase 2: Patients with carcinoma of the cervical esophagus.
- •For Phase 2: Patients with clinical evidence of metastasis to cervical or supraclavicular lymph nodes.
- •Prior chemotherapy or radiotherapy for esophageal or gastroesophageal junction cancer. Phase 1 patients with prior chemotherapy are permitted to enter.
- •Prior radiotherapy that would overlap the anticipated study treatment fields or radiotherapy to >30% of the marrow cavity (no prior chest irradiation).
- •Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction are also excluded.
- •Pregnant or nursing females. Fertile patients (male and female) must use effective contraception.
结局指标
主要结局
Phase 1: Safety and tolerability of AT-101 in combination with chemoradiotherapy, and determine a dose for Phase 2. Phase 2: Determine the pathologic complete response (pathCR) rate and to correlate tumor biomarker expression with clinical response.
时间窗: 1 year
次要结局
- To assess the safety and toxicity of chemoradiotherapy and AT-101 in patients with esophageal or gastroesophageal junction cancer.(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A phase I/II trial of preoperative chemoradiotherapy with gemcitabine in patients with pancreatic cancer and impaired renal functioJPRN-UMIN000016877Clinical Study Group of Osaka University8
已完成
不适用
Phase I/II study of preoperative chemoradiotherapy with Gemcitabine and S-1 for resectable pancreatic cancerJPRN-UMIN000002649Multicenter Clinical Study Group of Osaka63
Unknown
2 期
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell CarcinomaEsophageal TumorMetastatic Esophageal Squamous Cell CarcinomaNCT03800953National Taiwan University Hospital26
已完成
1 期
A phase I/II study of preoperative chemoradiotherapy with S-1, Celecoxib and Radiation for locally advanced rectal cancerRectal cancerJPRN-UMIN000012818Department of frontier surgery Graduate school of medicine, Chiba University20
已完成
1 期
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCProstate CancerNCT00286793Ascenta Therapeutics76